Skip to main content
. Author manuscript; available in PMC: 2024 Apr 25.
Published in final edited form as: JACC Heart Fail. 2023 Feb;11(2):211–223. doi: 10.1016/j.jchf.2022.11.007

Figure 4. Healthcare Expenditure of Heart Failure Patients Eligible for Vericiguat.

Figure 4.

Graph depicts cumulative costs in each patient group divided by number of patients at risk at that timepoint accounting for competing risk of death. Mean per-patient cost over 12-months post-discharge are shown for the hospitalized HF with EF<45% population (blue), FDA label patients (red), and VICTORIA eligible patients (black), respectively.